Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Nathan Fowler, Juthamas Sukbuntherng et al.|Journal of Clinical Oncology|2012

Cited by 1.1k